Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM IN PLASTIC CONTAINER versus LIQUAMAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM IN PLASTIC CONTAINER versus LIQUAMAR.
HEPARIN SODIUM IN PLASTIC CONTAINER vs LIQUAMAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, inducing conformational change that accelerates its inhibition of thrombin (factor IIa), factor Xa, and other coagulation factors (IXa, XIa, XIIa).
Liquamar (phenprocoumon) is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X in the liver by blocking the reduction of vitamin K to its active hydroquinone form.
Initial IV bolus of 80 units/kg followed by continuous IV infusion of 18 units/kg/hour; dose adjusted based on aPTT. Typical infusion range 10-30 units/kg/hour. Subcutaneous route: 5000 units every 8-12 hours for prophylaxis.
Initial: 0.5-1 mg/kg IV (not to exceed 2 mg). Maintenance: 0.5-2 mg IV q8-12h based on INR.
None Documented
None Documented
30-150 minutes (dose-dependent: 0.5-1.5 h at low doses, up to 2.5 h at high doses). Prolonged in hepatic or renal impairment.
The terminal elimination half-life of phenprocoumon is approximately 5 to 7 days (range 3-10 days). This long half-life results in sustained anticoagulant effect over days, requiring careful monitoring and dose adjustments.
Renal (predominantly), with minor biliary/fecal elimination. Clearance is dose- and concentration-dependent due to saturable binding.
Phenprocoumon is excreted primarily via renal elimination as metabolites (approximately 60-70% of the dose), with about 20% excreted in feces via biliary elimination. Less than 1% is excreted unchanged in urine.
Category A/B
Category C
Anticoagulant
Anticoagulant